Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Cladribine—a contentious therapeutic contender for MS

Nature Reviews Neurology volume 7, pages 425–427 (2011)Cite this article

Subjects

Cladribine, an oral immunomodulatory drug, has been denied FDA and European Medicines Agency approval for the treatment of relapsing–remitting multiple sclerosis. However, a new post-hoc analysis of CLARITY study data shows that cladribine treatment is associated with a significantly increased likelihood of sustained freedom from disease activity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kappos, L. et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362, 387–401 (2010).

    Article  CAS  Google Scholar 

  2. Cohen, J. A. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 362, 402–415 (2010).

    Article  CAS  Google Scholar 

  3. Giovannoni, G. et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N. Engl. J. Med. 362, 416–426 (2010).

    Article  CAS  Google Scholar 

  4. Merck Serono. Merck Serono: regulatory update on cladribine tablets. Merck Serono [online], (2011).

  5. Giovannoni, G. et al. Sustained disease-activity-free status in patients with relapsing–remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 10, 329–337 (2011).

    Article  CAS  Google Scholar 

  6. Gold, R. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS Drugs 25, 37–52 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Clinical Neuroimmunology, Ludwig Maximilians University Medical Clinic, Campus Grosshadern, Marchioninistraße 15, Munich, D-81377, Germany

    Reinhard Hohlfeld

Authors
  1. Reinhard Hohlfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R. Hohlfeld has received honoraria and grant and/or research support from Bayer Schering, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis and Teva, and has acted as a consultant for each of these companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hohlfeld, R. Cladribine—a contentious therapeutic contender for MS. Nat Rev Neurol 7, 425–427 (2011). https://doi.org/10.1038/nrneurol.2011.105

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2011.105

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing